Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies

Simple item page
dc.contributor.authorKoshiol, Jill
dc.contributor.authorCastro, Felipe
dc.contributor.authorKemp, Troy J.
dc.contributor.authorGao, Yu-Tang
dc.contributor.authorCarlos Roa, Juan
dc.contributor.authorWang, Bingsheng
dc.contributor.authorNogueira, Leticia
dc.contributor.authorCarlos Araya, Juan
dc.contributor.authorShen, Ming-Chang
dc.contributor.authorRashid, Asif
dc.contributor.authorHsing, Ann W.
dc.contributor.authorHildesheim, Allan
dc.contributor.authorFerreccio, Catterina
dc.contributor.authorPfeiffer, Ruth M.
dc.contributor.authorPinto, Ligia A.
dc.date.accessioned2025-01-23T21:30:05Z
dc.date.available2025-01-23T21:30:05Z
dc.date.issued2016
dc.description.abstractMost gallbladder cancer (GBC) cases arise in the context of gallstones, which cause inflammation, but few gallstone patients develop GBC. We explored inflammation/immune-related markers measured in bile and serum in GBC cases compared to gallstone patients to better understand how inflammatory patterns in these two conditions differ. We measured 65 immune-related markers in serum and bile from 41 GBC cases and 127 gallstone patients from Shanghai, China, and calculated age- and sex-adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for GBC versus gallstones. We then focused on the markers that were significantly elevated in bile and serum to replicate the findings in serum from 35 GBC cases and 31 gallstone controls from Chile. Comparing the highest versus lowest quantile, 15 markers (23%) were elevated in both serum and bile from GBC versus gallstone patients in the Shanghai study (p <0.05). The strongest OR was for CXCL8 (interleukin-8) in serum (96.8, 95% CI: 11.9-790.2). Of these 15 markers, 6 were also significantly elevated in serum from Chile (CCL20, C -reactive protein, CXCL8, CXCL10, resistin, serum amyloid A). Pooled ORs from Shanghai and Chile for these 6 markers ranged from 7.2 (95% CI: 2.8-18.4) for CXCL10 to 58.2 (95% CI: 12.4-273.0) for CXCL8. GBC is associated with inflammation above and beyond that generated by gallstones alone. This local inflammatory process is reflected systemically. Future longitudinal studies are needed to identify the key players in cancer development, which may guide translational efforts to identify individuals at high risk of developing GBC. Published by Elsevier Ltd.
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.cyto.2016.05.003
dc.identifier.eissn1096-0023
dc.identifier.issn1043-4666
dc.identifier.urihttps://doi.org/10.1016/j.cyto.2016.05.003
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/101445
dc.identifier.wosidWOS:000377228300029
dc.language.isoen
dc.pagina.final225
dc.pagina.inicio217
dc.revistaCytokine
dc.rightsacceso restringido
dc.subjectLocal inflammation
dc.subjectSystemic inflammation
dc.subjectGallbladder cancer
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAssociation of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies
dc.typeartículo
dc.volumen83
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas